Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

Business Leaders

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
HomeAll NewsMost read newsBusiness Leaders Biography
Portrait de N. Coles
Age : 61
Public asset : 2,888,226 USD
Country of residence : Unknown
Linked companies : Regeneron Pharmaceuticals, Inc. - Cerevel Therapeutics Holdings, Inc. - Yumanity Therapeutics, Inc.

Biography of N. Coles 
N. Anthony Coles is a businessperson who founded Yumanity Therapeutics, Inc. and Yumanity, Inc. and who has been at the helm of 9 different companies. He occupies the position of Executive Chairman & Chief Executive Officer at Cerevel Therapeutics Holdings, Inc., Executive Chairman & Chief Executive Officer for Cerevel Therapeutics LLC and Chief Executive Officer & Director at Cerevel Therapeutics, Inc. (both are subsidiaries of Cerevel Therapeutics Holdings, Inc.) and Non-Executive Chairman for Yumanity Therapeutics, Inc. Dr. Coles is also Member of Harvard Medical School and Council Member at Smithsonians National Museum of Natural History and on the board of 9 other companies. In the past he was Chairman of CRISPR Therapeutics AG, Chairman & Chief Executive Officer at Trate Enterprises, LLC, Senior Vice President-Strategy & Policy at Bristol Myers Squibb Co., VP-Hypertension & Heart Failure Business Group at Merck & Co., Inc., Senior Vice President-Commercial Operations at Vertex Pharmaceuticals, Inc., President & Chief Executive Officer of Onyx Pharmaceuticals, Inc., Executive Chairman for Yumanity, Inc. and President, Chief Executive Officer & Director at NPS Pharmaceuticals, Inc. He received a doctorate from Duke University, an undergraduate degree from The Johns Hopkins University and a graduate degree from Harvard University.


Current positions of N. Coles 
Holdings of N. Coles 
N. Coles : Personal Network 
Most Read News 
01/18ELON MUSK : Tesla investors urge judge to order Musk repay $13 billion for SolarCity deal
RE
01/11JAMIE DIMON : JPMorgan's Dimon says consumer loan growth may take 6-9 months to return to normal
RE
01/13JACK DORSEY : Jack Dorsey's Block to build an open bitcoin mining system
RE
01/14ELON MUSK : Musk says Tesla to accept dogecoin for merchandise
RE
01/20ALAN JOPE : Unilever strategy under scrutiny after short-lived GSK skirmish
RE
01/10BRUNELLO CUCINELLI : Luxury group Cucinelli posts 31% sales jump in 2021
RE
01/11CATHIE WOOD : ARK's Wood turns focus to deflation, 'stay connected' stocks
RE
01/12MARTIN SORRELL : Sorrell's S4 says trading well ahead of guidance
RE
01/13AMANCIO ORTEGA : Inditex founder Amancio Ortega buys Toronto's Royal Bank Plaza for $916 mln
RE
01/17ELON MUSK : Top Energy News of the Day
DJ
More news


© 2022 People and Ownership :   
N. Coles : Connections 


Latest news about N. Coles 
2021INSIDER SELL : Regeneron Pharmaceuticals
MT
2021N. Anthony Coles Transitions to the Role of Non-Executive Chair of the Board of Directors of Yumanity Therapeutics, Inc
CI
2021McKesson Corporation Announces N. Anthony Coles, M.D. Will Not Stand for Re-Election to Mckesson Board of Directors
CI
2020Yumanity Therapeutics Inc. completed the acquisition of Proteostasis Therapeutics, Inc. in a reverse merger transaction.
CI
2020Yumanity Therapeutics Inc. entered into an Agreement and Plan of Merger and Reorganization to acquire Proteostasis Therapeutics, Inc. for approximately $150 million in a reverse merger transaction.
CI
2017Regeneron Pharmaceuticals, Inc. Announces Executive Changes
CI
More news